Distribution of the study cohort by WHO-HAEM5 or ICC classifications
| . | ICC . | |||||
|---|---|---|---|---|---|---|
| . | . | AML-MR-M . | AML-TP53 . | AML-NOS . | AML-MR-CG . | Total . |
| WHO-HAEM5 | AML-MR | 218 | 100 | 4 | 32 | 354 |
| AML-DIFF | 7 | 1 | 32 | 7 | 47 | |
| AML-pCT | 9 | 11 | 5 | 3 | 28 | |
| AEL | - | 3 | - | - | 3 | |
| Total | 234 | 115 | 42 | 41 | 432 | |
| . | ICC . | |||||
|---|---|---|---|---|---|---|
| . | . | AML-MR-M . | AML-TP53 . | AML-NOS . | AML-MR-CG . | Total . |
| WHO-HAEM5 | AML-MR | 218 | 100 | 4 | 32 | 354 |
| AML-DIFF | 7 | 1 | 32 | 7 | 47 | |
| AML-pCT | 9 | 11 | 5 | 3 | 28 | |
| AEL | - | 3 | - | - | 3 | |
| Total | 234 | 115 | 42 | 41 | 432 | |
AML-MR: AML, myelodysplasia-related; AML-DIFF, AML by differentiation; AML-pCT, AML post cytotoxic therapy; AEL, Acute erythroid leukemia; AML-MR-M, AML with myelodysplasia-related gene mutations; AML-TP53, AML with mutated TP53; AML-NOS, AML not otherwise specified.